Patents by Inventor Nader Najafian

Nader Najafian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF COMPLEMENT FACTOR D INHIBITOR FOR TREATMENT OF LUPUS NEPHRITIS AND IMMUNOGLOBULIN A NEPHROPATHY
    Publication number: 20250090528
    Abstract: Disclosed herein are methods for treating lupus nephritis (LN) and/or immunoglobulin A (IgA) nephropathy in a subject. The methods include administering to the subject a therapeutically effective amount of a small molecule complement factor D inhibitor.
    Type: Application
    Filed: October 13, 2022
    Publication date: March 20, 2025
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Nader Najafian, Katherine Gayle Garlo, Steven David Podos
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Publication number: 20240301406
    Abstract: The invention relates to methods for treating subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria, using iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and anti-C5 antibodies, e.g., eculizumab.
    Type: Application
    Filed: July 6, 2023
    Publication date: September 12, 2024
    Inventors: Nader Najafian, Jae Kim, Mustafa Varoglu, Gabriel Robbie
  • DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING C5-MEDIATED GLOMERULAR NEPHRITIS (GN), INCLUDING LUPUS NEPHRITIS (LN) AND/OR IGA NEPHROPATHY (IGAN)
    Publication number: 20230348579
    Abstract: Provided are dosages and methods for clinical treatment of C5-mediated glomerular nephritis (GN), including lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN), in human patients using an anti C5 antibody, or antigen binding fragment thereof (e.g., such as ravulizumab (ULTOMIRIS®)), optionally together with background therapy for treating LN (e.g., an immuno-suppressant) or background therapy for treating IgAN (e.g., renin-angiotensin system (RAS) inhibiting medication).
    Type: Application
    Filed: September 16, 2021
    Publication date: November 2, 2023
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventor: Nader Najafian
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Publication number: 20210171946
    Abstract: The invention relates to methods for treating subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria, using iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and anti-C5 antibodies, e.g., eculizumab.
    Type: Application
    Filed: October 14, 2020
    Publication date: June 10, 2021
    Inventors: Nader Najafian, Jae Kim, Mustafa Varoglu, Gabriel Robbie
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Publication number: 20190256845
    Abstract: The invention relates to methods for treating subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria, using iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and anti-C5 antibodies, e.g., eculizumab.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 22, 2019
    Inventors: Nader Najafian, Jae Kim, Mustafa Varoglu, Gabriel Robbie
  • Methods of Using Anti-Thymocyte Globulin and Related Agents
    Publication number: 20130344092
    Abstract: Novel uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-? are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicants: The Brigham and Women's Hospital, Inc., Genzyme Corporation
    Inventors: Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson
  • Methods of Using Anti-Thymocyte Globulin and Related Agents
    Publication number: 20100034782
    Abstract: Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.
    Type: Application
    Filed: May 31, 2007
    Publication date: February 11, 2010
    Inventors: Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson